Cargando…
The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
Diabetes is a leading cause of cardiovascular disease and its associated morbidity. While the medical community has had access to numerous glucose lowering therapies over the last decades, it was not until recently that newer agents demonstrated improvement in cardiovascular outcomes. In particular,...
Autores principales: | Dhindsa, Devinder S., Sandesara, Pratik B., Shapiro, Michael D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282028/ https://www.ncbi.nlm.nih.gov/pubmed/30555833 http://dx.doi.org/10.3389/fcvm.2018.00160 |
Ejemplares similares
-
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
por: Dhindsa, Devinder S., et al.
Publicado: (2020) -
Cohort profile: the Emory Cardiovascular Biobank (EmCAB)
por: Ko, Yi-An, et al.
Publicado: (2017) -
Editorial: New mechanisms and drugs for the treatment of cardiovascular disease with diabetes
por: Zhang, Shanshan, et al.
Publicado: (2023) -
Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023) -
TREK channels in Mechanotransduction: a Focus on the Cardiovascular System
por: Herrera-Pérez, Salvador, et al.
Publicado: (2023)